Real-time Analysis of Skin Biopsy Specimens With 2-Photon Fluorescence Microscopy.
Vincent D Ching-Roa, Chi Z Huang, Sherrif F Ibrahim...
https://pubmed.ncbi.nlm.nih.gov/36069886/Actively Recruiting
Led by University of Rochester · Updated on 2026-08-19
644
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the use of two-photon fluorescence microscopy TPFM to examine dermatologic biopsy specimens. The study aims to determine how well TPFM images, taken from biopsies in a clinic and reviewed by pathologists, agree with traditional histology results. This could help assess TPFMs accuracy in diagnosing various skin conditions such as basal cell carcinoma, squamous cell carcinoma, and melanocytic lesions. Participants biopsy specimens, including punch, excisional, or shave biopsies, will be imaged using two-photon fluorescence microscopy shortly after removal. These images will then be compared with conventional histology slides, which are reviewed by expert pathologists to establish an official diagnosis. The study also involves evaluation by a machine learning model to predict diagnoses from TPFM images. During the study, biopsy specimens will be processed and imaged with TPFM, followed by standard histological processing and scanning of slides for comparison. Researchers will measure the sensitivity and specificity of TPFM in predicting the official patient diagnoses, typically assessed 1 to 2 weeks after the biopsy procedure. The study duration extends until April 2028, with ongoing monitoring of diagnostic agreement between TPFM and conventional histology.
CONDITIONS
Two-photon Fluorescence Microscopy of Dermatologic Biopsies
M
Michael G Giacomelli, Ph.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Rochester
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | TPFM imaging of biopsy (investigational) | Standard paraffin‑section histology |
|---|---|---|
| What it is | A rapid imaging technique that captures histology‑like fluorescence images from freshly excised dermatologic biopsy specimens without slide preparation | Traditional paraffin‑section histopathology with hematoxylin‑eosin staining requiring tissue processing and slide preparation |
| Role in diagnostic process | Used immediately on fresh biopsy specimens as the investigational diagnostic method under evaluation | Serves as the reference standard for confirming diagnosis after conventional tissue processing |
| Diagnostic goal | To predict official patient diagnosis rapidly from biopsy using fluorescence imaging | To confirm diagnosis using processed tissue and standard histological analysis |
| How it is performed | Biopsy tissue is imaged within minutes using TPFM on fresh specimens without slide preparation | Biopsy specimens are processed, embedded in paraffin, sectioned, stained with H&E, and evaluated by pathologist |
| Evidence status | Pilot data show high diagnostic concordance with conventional histology for basal cell and squamous cell carcinoma (≈93% accuracy, 100% sensitivity for BCC, 89% sensitivity for SCC) | Well‑established diagnostic accuracy in clinical pathology with decades of validated use |
| Important risks | Not reported; safety risks not established | Requires tissue processing and handling but established safety profile in pathology |
| Important limitations | Data limited to pilot cohort; requires validation in larger studies and not yet broadly available | Tissue processing delays diagnosis by days to weeks and requires technical lab infrastructure |
| Patient impact | Potential for same‑visit diagnosis and treatment decisions, reducing delays | Requires waiting for histology results before treatment decisions |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Typically 1 to 2 weeks after biopsy
Participants' biopsy specimens will be imaged using two-photon fluorescence microscopy shortly after removal. The same specimens will undergo conventional histology processing for diagnostic comparison by pathologists.
1 to 2 visits
Duration - Up to 2 weeks after diagnosis
Researchers will evaluate how well two-photon fluorescence microscopy predicts the official patient diagnoses by measuring sensitivity and specificity.
1 visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Vincent D Ching-Roa, Chi Z Huang, Sherrif F Ibrahim...
https://pubmed.ncbi.nlm.nih.gov/36069886/University of Rochester
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor